Aim: To investigate the effects of once‐daily oral semaglutide 50 mg on energy intake, appetite, control of eating and gastric emptying. Methods: A clinical pharmacology, double‐blind study was conducted in 61 adults with obesity randomized to once‐daily oral semaglutide (dose‐escalated to 50 mg) or placebo for 20 weeks. Energy intake was measured during an ad libitum lunch, and participant‐reported appetite ratings and Control of Eating Questionnaire responses were assessed. Gastric emptying was measured using paracetamol absorption following a standardized breakfast. Results: The relative change from baseline in ad libitum energy intake at week 20 (primary endpoint) was −39.2% points (95% confidence interval −59.0%, −19.4%) with semaglutide compared with placebo. Body weight was reduced by 9.8% with semaglutide and by 1.5% with placebo. Semaglutide reduced hunger, increased fullness and satiety, and was associated with fewer food cravings and better control of eating versus placebo. No statistically significant difference in gastric emptying was observed at week 20. Conclusions: In participants with obesity, once‐daily oral semaglutide 50 mg reduced energy intake, body weight and appetite, and improved control of eating. There was no evidence of delayed gastric emptying at week 20, as measured through paracetamol absorption.
Objective: The hormone peptide YY (PYY; cleaved into Y2‐selective form PYY3‐36) is an attractive candidate for use as a complementary pharmacotherapy for obesity along with glucagon‐like peptide‐1 (GLP‐1) receptor agonists. This series of studies investigated a novel long‐acting PYY3‐36 analogue (PYY1875) alone and as an add‐on to semaglutide for treatment of obesity.Methods: Weight loss and food intake were first investigated in obese male rats, followed by phase 1 and 2 clinical studies investigating efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of PYY1875 as monotherapy and in combination with semaglutide in participants with overweight or obesity.Results: PYY1875 induced additional body weight loss in semaglutide‐treated obese rats. In the phase 1 study, all doses of PYY1875 alone and coadministered with semaglutide were tolerated. In the phase 2 study, a modest but not clinically meaningful treatment effect of PYY1875 1.0 mg versus placebo as an add‐on to semaglutide 2.4 mg was observed. However, gastrointestinal‐related adverse events were common with the 1.0‐mg PYY1875 dose, and the 2.0‐mg PYY1875 dose escalation regimen was not tolerated (both as add‐ons to semaglutide).Conclusions: PYY1875 showed modest efficacy as an add‐on to semaglutide for weight management in people with obesity, but the treatment was not well tolerated.